Company: NCEL
Filing Date: 2025-05-16
Form Type: 20-F
Source: 0001213900-25-044868
Chunk: 259

Company: NewcelX Ltd.
Filing Date: 2025-05-16
Form: 20-F
Item: Item 4
Chunk 259
---
 of December 31, 2024.

Income Taxation

We
incur tax loss carryforwards generating deferred tax assets against which a valuation allowance is recorded when it is not more likely
than not that the tax benefit can be realized. Judgment is required to determine the use of tax loss carryforwards. Management’s
current judgment is that it is not more likely than not that the tax benefits can be realized and a full valuation allowance is therefore
recognized.

ITEM 6. DIRECTORS,
SENIOR MANAGEMENT AND EMPLOYEES

A Directors
and Senior Management

The
following table sets forth information regarding our directors and senior management and directors as of May 15, 2025:

  Name                              Age      Position                          Initial  
                                                                               Year of  
                                                                           Appointment  
 ────────────────────────────────────────────────────────────────────────────────────────
  Directors                                                                             
  Ronald Hafner (1)(3)               61      Chairman and Director                2015  
  Alexander Zwyer                    56      Chief Executive Officer              2015  
  Nicole Fernandez-McGovern          52      Chief Financial Officer              2024  
  Eric Konofal                       57      Chief Scientific Officer             2021  
  Gian-Marco Rinaldi (1)(2)(3)       56      Director                             2021  
  Florence Allouche Aknin (3)        58      Director                             2024  
  Olivier Samuel (3)                 50      Director                             2024  

  (1)      Member of Compensation,            

  (2)      Member of the Audit Committee  

  (3)      Independent Director (as     

In
general, members of our board of directors are elected by our shareholders and elected to serve for a one-year period.

Ronald Hafner,
Chairman of the Board of Directors

Ronald
Hafner

Alexander Zwyer,
Chief Executive Officer and Director

Alexander
Zwyer

Nicole Fernandez - McGovern,
Chief Financial Officer

Nicole
Fernandez-McGovern

Eric Konofal,
Chief Scientific Officer

Eric
Konofal, MD, Ph. D.

Gian-Marco Rinaldi, Director

Gian-Marco
Rinaldi

Florence Allouche Aknin, Director

Florence
Allouche Aknin

Olivier Samuel,
Director

Olivier
Samuel

Olivier Samuel,
Director

Mr. Samuel